KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Expenditures (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Capital Expenditures data on record, last reported at $114000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures fell 82.88% year-over-year to $114000.0; the TTM value through Sep 2025 reached $612000.0, down 50.88%, while the annual FY2024 figure was $1.5 million, 69.71% up from the prior year.
  • Capital Expenditures reached $114000.0 in Q3 2025 per NKTR's latest filing, up from $37000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.9 million in Q4 2021 and bottomed at $2000.0 in Q1 2025.
  • Average Capital Expenditures over 5 years is $1.2 million, with a median of $433000.0 recorded in 2023.
  • Peak YoY movement for Capital Expenditures: skyrocketed 1918.18% in 2024, then crashed 98.73% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $5.9 million in 2021, then tumbled by 91.32% to $512000.0 in 2022, then plummeted by 53.71% to $237000.0 in 2023, then soared by 93.67% to $459000.0 in 2024, then plummeted by 75.16% to $114000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $114000.0 in Q3 2025, $37000.0 in Q2 2025, and $2000.0 in Q1 2025.